

FORM 7

MONTHLY PROGRESS REPORT

Name of CSE Issuer: Blueberries Medical Corp. (the "Company or "Issuer").

Trading Symbol: BBM

Number of Outstanding Listed Securities: 126,701,831

Date: **December 2020**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Blueberries Medical Corp. ("Blueberries") is executing its strategy to become a large scale producer and processor of naturally grown premium quality cannabis and a leading Latin American supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products with its primary operations situated in the Bogotá Savannah in central Colombia.

The Company has commenced sales of its proprietary cultivars approved by the Colombian Institute of Agriculture ("ICA"). Blueberries has entered into multiple sales agreements to distribute its proprietary genetics to licensed producers located in Bogota Savannah, the region where the Company operates. Under the agreements, the Company will leverage contract growers to produce the Company's registered non-psychoactive cannabidiol ("CBD") strains approved by ICA. These proprietary cultivars were developed and tested by the Company's agronomic team and optimized for growth in the local climate.

Production from contract growers will be processed at the Company's extraction facility under arrangements whereby Blueberries will retain a certain portion of the extracted product for resale as compensation for these services. Such arrangements provide the Company with premium extracts without the associated cultivation capital expenditures and related risks.

2. Provide a general overview and discussion of the activities of management.

On December 4, 2020, the Issuer announced that the Company completed the acquisition of BBV Labs Inc. ("BBV"), a corporation formed under the laws of the Republic of Panama, pursuant to the previously announced share purchase agreement (the "Purchase Agreement").

With the Purchase Agreement Blueberries will have the rights to acquire

cannabis cultivation, processing, manufacturing, and other rights in Argentina, pursuant to a definitive joint venture agreement with the Argentinean state-owned company Cannabis Avatara, S.E. ("Cannava") and BBV, (the "Joint Venture"). The Joint Venture with Cannava allows the Company to develop and cultivate cannabis on a 3.2 million square foot (74 acres or 30 hectares) prime agricultural property. Cannava will contribute the land to the Joint Venture as well as all required permits and authorization necessary to import seeds, cultivate, grow, and harvest cannabis, process cannabis and extract cannabis oil and other derivative products for scientific, medicinal, and therapeutic purposes and to export cannabis and derivative products and import and export related equipment and products.

The Purchase Agreement was amended to change its terms to reflect the payment of the purchase price to be satisfied by Blueberries issuing 3,000,000 common shares in the capital of the Company to the vendors.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State

how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	3,000,000	Acquisition of BBV	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

N/A

15. Provide details of any loans to or by Related Persons.

N/A

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: January 8, 2021.

Ian D. Atacan
Name of Director or Senior Officer

"Ian D. Atacan"
Signature

Chief Financial Officer
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer	December 2020	YY/MM/DD
Blueberries Medical Corp.		2021/01/08
Issuer Address		
885 West Georgia Street, Suite 2200, HSBC Building		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 3E8		
Contact Name	Contact Position	Contact Telephone No.
Ian Atacan	CFO	(416) 562-3220
Contact Email Address	Web Site Address	
iatacan@blueberriesmed.com	www.blueberriesmed.com	